SEC Form 8-K Summary
Business Context and Reporting Period
The provided filing is a Form 8-K for Tivic Health Systems, Inc., not Valion Bio, Inc. The report concerns events dated November 10–15, 2021. Tivic was an emerging growth company, with common stock trading under the symbol TIVC on Nasdaq.
Key Financial and Capitalization Information
- The company priced its initial public offering at $5.00 per share.
- The IPO included 3,000,000 common shares and generated $15.0 million of gross proceeds.
- Underwriters received a 45-day option to purchase up to 450,000 additional shares for over-allotments.
- The filing text does not provide revenue, profit or loss, operating cash flow, margins, debt, cash balance, net IPO proceeds, or liquidity metrics.
Material Changes and Corporate Actions
- The company entered into an underwriting agreement with ThinkEquity LLC in connection with the IPO.
- The IPO registration statement on Form S-1 was declared effective by the SEC on November 10, 2021.
- On November 12, 2021, the company filed an amended and restated certificate of incorporation and executed amended and restated bylaws, both previously approved by the board and stockholders.
- The IPO closing was announced on November 15, 2021.
Guidance, Outlook, Risks and Unusual Items
The filing provides no financial guidance, operating outlook, management forecast, or quantitative risk analysis. The principal unusual item is the company’s initial public offering and related potential dilution from the underwriters’ over-allotment option. The filing text does not state how IPO proceeds will be used or identify any material contingencies.
Important Facts to Verify
- Confirm the issuer identity: the source filing identifies Tivic Health Systems, Inc., while the request metadata identifies Valion Bio, Inc.
- Verify whether the 450,000-share over-allotment option was exercised and determine the resulting shares outstanding.
- Review the underwriting agreement for underwriting discounts, commissions, indemnification, and other offering expenses.
- Review subsequent financial filings for net IPO proceeds, cash runway, operating losses, debt, and use of proceeds.
- Confirm the effective dates and provisions of the amended certificate of incorporation and bylaws.